Compare Charlie Hospital Semarang Tbk. (RSCH) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charlie Hospital Semarang Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Charlie Hospital Semarang Tbk. trades at Rp430 (market cap 1.11T, 25.61M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Charlie Hospital Semarang Tbk. is far larger — about 10.6× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| RSCH | SCPI | |
|---|---|---|
Market Cap | 1.11T | 104.4B |
Volume | 25.61M | — |
Lot | 256.07K | — |
Turnover | 10.76B | — |
Average Price | 420.16 | — |
Value | 10.76B | — |
Indicative Equilibrium Price | 430 | — |
Indicative Equilibrium Volume | 1.46K | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charlie Hospital Semarang Tbk.
PT Charlie Hospital Semarang, Tbk (the "Company") was established based on Deed No. 35 dated 11 February 2019, which was made before Notary Nur Hadi, SH, MKn, notary in Kendal Regency and has been approved by the Minister of Law and Human Rights of the Republic of Indonesia based on Decree No. AHU-0008598.AH.01.01. Year 2019 February 11, 2019. The company started its commercial operations on September 23, 2019.
Read more on RSCH →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
